79 Viral co-infections in SARS-CoV-2 4 Methods Study design The International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study is an ongoing prospective observational cohort study recruiting inpatients in over 300 hospitals in England, Scotland, and Wales (National Institute for Health Research (NIHR) Clinical Research Network Central Portfolio Management System ID: 14152) performed by the ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C). The study protocol is available online (isaric4c.net/protocols). Patients with confirmed or clinician-defined high-likelihood of SARS-CoV-2 infection were eligible for inclusion. A pre-specified case report form was used for data collection. Ethical approval was given by the South Central-Oxford C Research Ethics Committee in England (13/ SC/0149), the Scotland A Research Ethics Committee (20/SS/0028), and the WHO Ethics Review Committee (RPC571 and RPC572, April 2013). For this analysis, we included only adults (≥18 years) with RT-PCR confirmed SARS-CoV-2 infection who were hospitalised between 6th February, 2020 and 8th December, 2021. Testing for additional respiratory viruses was done using RT-PCR for influenza virus (A or B), adenovirus and respiratory syncytial virus (RSV), at the discretion of the treating clinician. The influenza type (A or B) was not registered in the database. Subjects were included in the co-infected group if they had positive test results registered for influenza virus, adenovirus or RSV. Patients were included in the SARS-CoV-2 mono-infected group if they had a negative test result registered for influenza virus, adenovirus or RSV. Comorbidities were summarised as an overall comorbidity count, with each comorbidity having the same weight. Included comorbidities were (clinician defined) obesity, chronic cardiac disease, chronic pulmonary disease (excluding asthma), asthma, liver disease, diabetes mellitus (type 1 or 2), chronic neurological disease, malignant neoplasm, rheumatological disease, dementia, HIV/ AIDS and chronic kidney disease. The main outcomes were the need for IMV and in-hospital mortality. This project had several objectives. First, because of limited testing for respiratory viral co-infections during the pandemic we suspected the group that was tested was different from the group that was not tested. Therefore, our first objective was to describe and compare characteristics and outcome for patients who were tested for a second viral respiratory co-infection with influenza virus (A or B), adenovirus or RSV to those who were not tested. In the subgroup of tested patients, we then proceeded to analyse characteristics and outcome between patients who tested positive to those who tested negative. In order to correct for possible differences between the tested and not tested population and to generalise our conclusion to the complete hospital population, we performed an inverse probability weighting (IPW) analysis.
RkJQdWJsaXNoZXIy MTk4NDMw